Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 137

Results For "NAL"

5545 News Found

NHA and IIT Kanpur sign MoU for development of digital public goods for AI in healthcare
Digitisation | September 11, 2024

NHA and IIT Kanpur sign MoU for development of digital public goods for AI in healthcare

The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform


Merck announces positive top-line results from Phase 3 trial evaluating efficacy and safety of Gardsil 9
Diagnostic Center | September 11, 2024

Merck announces positive top-line results from Phase 3 trial evaluating efficacy and safety of Gardsil 9

The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9


Health Ministry releases
Policy | September 10, 2024

Health Ministry releases "Health Dynamics of India (Infrastructure and Human Resources) 2022-23"

The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions


Aster Health Academy to offer advanced medical courses
News | September 10, 2024

Aster Health Academy to offer advanced medical courses

The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation


Atal Innovation Mission, NITI Aayog hosts 20th MedTech Mitra Technical advisory meeting
Policy | September 10, 2024

Atal Innovation Mission, NITI Aayog hosts 20th MedTech Mitra Technical advisory meeting

MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions


Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial
Diagnostic Center | September 10, 2024

Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial

TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population


Briefs: Wanbury and Bafna Pharmaceuticals
News | September 10, 2024

Briefs: Wanbury and Bafna Pharmaceuticals

Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API


Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study
News | September 10, 2024

Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study

The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme


Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial
Diagnostic Center | September 09, 2024

Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients


Lilly and EVA Pharma collaborate to expand access to baricitinib across 49 low- to middle-income countries in Africa
News | September 09, 2024

Lilly and EVA Pharma collaborate to expand access to baricitinib across 49 low- to middle-income countries in Africa

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases